Literature DB >> 3263476

Specific cytotoxic activity of T lymphocyte clones derived from a patient with gliosarcoma.

S Miyatake1, H Kikuchi, K Iwasaki, J Yamashita, Z Y Li, Y Namba, M Hanaoka.   

Abstract

Eleven lymphocyte clones were established from the peripheral blood lymphocytes of a patient with gliosarcoma by means of autologous tumor stimulation and the limiting-dilution technique with recombinant interleukin-2. Ten of the 11 clones were cytotoxic against the autologous tumor cell line GI-1. Seven of the 10 clones were also cytotoxic against allogeneic brain-tumor lines and HeLa cells, one clone was cytotoxic against several target cells, and two clones were specifically cytotoxic against GI-1 and allogeneic brain-tumor cells. One of the 11 clones was not cytotoxic against any target cells tested. Lymphokine-activated killer cells induced by recombinant interleukin-2 alone exhibited cytotoxic activity against all target tumor cells tested. Surface phenotypic analysis revealed that all lymphocyte clones expressed CD3 antigen, some expressed CD4 antigen, and others expressed CD8 antigen. These clones seemed to be antigen-specific cytotoxic T lymphocyte clones. Analysis with these antigen-specific cytotoxic T lymphocyte clones may be useful in the elucidation of tumor-specific or tumor-associated antigens on autologous tumor cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3263476     DOI: 10.3171/jns.1988.69.5.0751

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  5 in total

Review 1.  All in the head: obstacles for immune rejection of brain tumours.

Authors:  Paul R Walker; Thomas Calzascia; Pierre-Yves Dietrich
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

2.  Induction of auto-logous human cytotoxic T lymphocytes (CTL) from peripheral blood against tumor cells.

Authors:  T Ohno
Journal:  Cytotechnology       Date:  1997-01       Impact factor: 2.058

3.  Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas.

Authors:  K B Quattrocchi; C H Miller; S Cush; S A Bernard; S T Dull; M Smith; S Gudeman; M A Varia
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

4.  Effect of irradiation on transforming growth factor-beta secretion by malignant glioma cells.

Authors:  E Satoh; H Naganuma; A Sasaki; M Nagasaka; H Ogata; H Nukui
Journal:  J Neurooncol       Date:  1997-07       Impact factor: 4.130

5.  Reduction of end-stage malignant glioma by injection with autologous cytotoxic T lymphocytes.

Authors:  H Tsurushima; S Q Liu; K Tuboi; A Matsumura; Y Yoshii; T Nose; K Saijo; T Ohno
Journal:  Jpn J Cancer Res       Date:  1999-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.